恩格列净治疗2型糖尿病患者心脏重构的Meta分析
Empagliflozin in Patients with Type 2 Diabetes: A Meta-Analysis of Cardiovascular Remodeling
DOI: 10.12677/ACM.2021.112067, PDF,   
作者: 欧振飞, 商 玲, 徐海凌, 张雪娟：青岛大学附属医院全科医学科，山东 青岛
关键词: 恩格列净；2型糖尿病；左心室重构；Empagliflozin； Type 2 Diabetes； Left Ventricular Remodeling
摘要: 目的：探讨恩格列净对改善2型糖尿病(T2DM)患者左心室重构的疗效。方法：我们在PubMed、EMBASE、Cochrane Library、Web of Science、CNKI数据库、VIP数据库、Wanfang数据库，共7个电子数据库中搜索了在2020年9月30日之前发表的文章，包括中文和英文。我们在分析中纳入了随机对照试验。评价治疗组与对照组左室超声心动图参数平均变化的差异。结果：Meta分析结果显示，LAVI (WMD = −6.29, 95%CI (−10, −2.58)，P < 0.001), E/e′ (WMD = −2.15, 95%CI (−4.08, −0.21), P = 0.003), LVEF (WMD = 3.67, 95%CI (0.59, 6.75), P = 0.02), LVEDV (WMD = −1.99, 95%CI (−26.49, −22.50), P = 0.87), LVESV (WMD = −8.36, 95%CI (−17.36, −0.65), P = 0.07)。结论：恩格列净可显著降低2型糖尿病患者的LAVI和E/e′，改善患者心功能。
Abstract: Objective: The purpose of this meta-analysis is to explore the efficacy of empagliflozin in improving left ventricular (LV) remodeling in patients with type 2 diabetes (T2DM). Methods: We searched articles published before September 30, 2020, Language including Chinese and English, in 7 electronic databases: PubMed, EMBASE, Cochrane Library, Web of Science, CNKI database, VIP database and Wanfang database. We included randomized controlled trials in this meta-analysis to evaluate the difference in mean changes in left ventricular echocardiographic parameters between the treatment and control groups. Results: The results of meta-analysis showed that LAVI (WMD = −6.29, 95%CI (−10, −2.58), P < 0.001), E/e′ (WMD = −2.15, 95%CI (−4.08, −0.21), P = 0.003), LVEF (WMD = 3.67, 95%CI (0.59, 6.75), P = 0.02), LVEDV (WMD = −1.99, 95%CI (−26.49, −22.50), P = 0.87), LVESV (WMD = −8.36, 95%CI (−17.36, −0.65), P = 0.07). Conclusions: Empagliflozin can significantly reduce the LAVI and E/e′ of patients with Type 2 diabetes. It can improve cardiac function of patients.
文章引用：欧振飞, 商玲, 徐海凌, 张雪娟. 恩格列净治疗2型糖尿病患者心脏重构的Meta分析[J]. 临床医学进展, 2021, 11(2): 469-475. https://doi.org/10.12677/ACM.2021.112067

参考文献

[1] International Diabetes Federation (2013) IDF Diabets Atlas. 6th Edition, International Diabetes Federation, Brussels.
[2] Di Angelantonio, E., Kaptoge, S., Wormser, D., Willeit, P., et al. (2015) Association of Cardiometabolic Multimorbidity with Mortality. JAMA, 314, 52-60. [Google Scholar] [CrossRef] [PubMed]
[3] From, A.M., Scott, C.G. and Chen, H.H. (2010) The Development of Heart Failure in Patients with Diabetes Mellitus and Pre-Clinical Diastolic Dysfunction a Population-Based Study. Journal of the American College of Cardiology, 55, 300-305. [Google Scholar] [CrossRef] [PubMed]
[4] Dawson, A., Morris, A.D. and Struthers, A.D. (2005) The Epidemiology of Left Ventricular Hypertrophy in Type 2 Diabetes Mellitus. Diabetologia, 48, 1971-1979. [Google Scholar] [CrossRef] [PubMed]
[5] Stratton, I.M., Adler, A.I., Neil, H.A., Matthews, D.R., Manley, S.E., Cull, C.A., et al. (2000) Association of Glycaemia with Macrovascular and Microvascular Complications of Type 2 Diabetes (UKPDS 35): Prospective Observational Study. BMJ, 321, 405-412. [Google Scholar] [CrossRef] [PubMed]
[6] Neal, B., Perkovic, V., Mahaffey, K.W., de Zeeuw, D., Fulcher, G., Erondu, N., et al. (2017) Canagliflozin Andcardiovascular and Renal Events in Type 2 Diabetes. New England Journal of Medicine, 377, 644-657. [Google Scholar] [CrossRef] 
[7] Wiviott, S.D., Raz, I., Bonaca, M.P., Mosenzon, O., Kato, E.T., Cahn, A., et al. (2019) Dapagliflozin and Cardiovascularoutcomes in Type 2 Diabetes. New England Journal of Medicine, 380, 347-357. [Google Scholar] [CrossRef] 
[8] Perkovic, V., Jardine, M.J., Neal, B., Bompoint, S., Heerspink, H.J.L., Charytan, D.M., et al. (2019) Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. New England Journal of Medicine, 380, 2295-306. [Google Scholar] [CrossRef] 
[9] Zinman, B., Wanner, C., Lachin, J.M., Fitchett, D., Bluhmki, E., Hantel, S., et al. (2015) Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. New England Journal of Medicine, 373, 2117-2128. [Google Scholar] [CrossRef] 
[10] 中华医学会心血管病学分会心力衰竭学组, 中国医师协会心力衰竭专业委员会, 中华心血管病杂志编辑委员会. 中国心力衰竭诊断和治疗指南2018 [J] .中华心血管病杂志, 2018, 46(10): 760-789.
[11] Abdi-Ali, A., Miller, R.J.H., Southern, D., Zhang, M., Mikami, Y., Knudtson, M., et al. (2018) LV Mass Independently Predicts Mortality and Need for Future Revascularization in Patients Undergoing Diagnostic Coronary Angiography. JACC: Cardiovascular Imaging, 11, 423-433. [Google Scholar] [CrossRef] [PubMed]
[12] Mathew, J., Sleight, P., Lonn, E., Johnstone, D., Pogue, J., Yi, Q.L., et al. (2001) Reduction of Cardiovascular Risk by Regression of Electrocardiographic Markers of Left Ventricular Hypertrophy by the Angiotensin-Converting Enzyme Inhibitorramipril. Circulation, 104, 1615-1621. [Google Scholar] [CrossRef] [PubMed]
[13] Sattar, N., McLaren, J., Kristensen, S.L., Preiss, D. and McMurray, J.J. (2016) SGLT2 Inhibitionand Cardiovascular Events: Why did EMPA-REG Outcomes Surprise and What Were the Likely Mechanisms? Diabetologia, 59, 1333-1339. [Google Scholar] [CrossRef] [PubMed]
[14] Shubrook, J.H., Bokaie, B.B. and Adkins, S.E. (2015) Empagliflozin in the Treatment of Type 2 Diabetes: Evidence to Date. Drug Design, Development and Therapy, 9, 5793-5803. [Google Scholar] [CrossRef] 
[15] Chilton, R., Tikkanen, I., Cannon, C.P., Crowe, S. Woerle, H.J., Broedl, U.C., et al. (2015) Effects of Empagliflozin on Blood Pressure and Markers of Arterial Stiffness and Vascular Resistance in patients with Type 2 Diabetes. Diabetes, Obesity and Metabolism, 17, 1180-1193. [Google Scholar] [CrossRef] [PubMed]
[16] Sano, M. (2018) A New Class of Drugs for Heart Failure: SGLT2 Inhibitors Reduce Sympathetic Overactivity. Journal of Cardiology, 71, 471-476. [Google Scholar] [CrossRef] [PubMed]
[17] Brown, A.J.M., Lang, C., McCrimmon, R. and Struthers, A. (2017) Does Dapagliflozin Regress Left Ventricularhypertrophy in Patients with Type 2 Diabetes? A Prospective, Double-Blind, Randomised, Placebo-Controlled Study. BMC Cardiovascular Disorders, 17, Article No. 229. [Google Scholar] [CrossRef] [PubMed]
[18] Verma, S., Garg, A., Yan, A.T., Gupta, A.K., Al-Omran, M., Sabongui, A., et al. (2016) Effect of Empagliflozin on Left Ventricular Mass and Diastolic Function in Individuals with Diabetes: An Important Clue to the EMPA- REGOUTCOME Trial? Diabetes Care, 39, e212-e213. [Google Scholar] [CrossRef] [PubMed]
[19] Matsutani, D., Sakamoto, M., Kayama, Y., Takeda, N., Horiuchi, R. and Utsunomiya, K. (2018) Effect of Canagliflozin on Left Ventricular Diastolic Function in Patients with Type 2 Diabetes. Cardiovascular Diabetology, 17, Article No. 73. [Google Scholar] [CrossRef] [PubMed]
[20] Soga, F., Tanaka, H., Tatsumi, K., Mochizuki, Y., Sano, H., Toki, H., Matsumoto, K., et al. (2018) Impact of Dapagliflozin on Left Ventricular Diastolicfunction of Patients with Type 2 Diabetic Mellitus with Chronic Heart Failure. Cardiovascular Diabetology, 17, Article No.132. [Google Scholar] [CrossRef] [PubMed]
[21] Sakai, T. and Miura, S. (2018) Abstract 17041: Effectof Sodium-Glucose Cotransporter 2 Inhibitor on Vascular Endothelial Function and Diastolic Function in Patients with Heart Failure with Preserved Ejection Fraction (HFpEF). Circulation, 136, Article ID: A17041.
[22] Tochiya, M., Makino, H., Tamanaha, T., Matsuo, M., Hishida, A., Koezuka, R., et al. (2020) Effect of Tofogliflozin on Cardiac and Vascular Endothelial Function in Patients with Type 2 Diabetes and Heart Diseases: A Pilot Study. Journal of Diabetes Investigation, 11, 400-404. [Google Scholar] [CrossRef] [PubMed]

为你推荐